Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) Return on Capital Employed (2016 - 2026)

Neuroone Medical Technologies filings provide 12 years of Return on Capital Employed readings, the most recent being 108.18% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 6906.0% to 108.18% in Q1 2026 year-over-year; TTM through Mar 2026 was 108.18%, a 6906.0% increase, with the full-year FY2025 number at 73.19%, up 18978.0% from a year prior.
  • Return on Capital Employed hit 108.18% in Q1 2026 for Neuroone Medical Technologies, down from 90.76% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 49.73% in Q3 2025 to a low of 405.98% in Q3 2024.
  • Median Return on Capital Employed over the past 5 years was 137.19% (2023), compared with a mean of 173.64%.
  • Biggest five-year swings in Return on Capital Employed: tumbled -18117bps in 2024 and later soared 35625bps in 2025.
  • Neuroone Medical Technologies' Return on Capital Employed stood at 90.91% in 2022, then tumbled by -168bps to 243.18% in 2023, then skyrocketed by 36bps to 155.59% in 2024, then skyrocketed by 42bps to 90.76% in 2025, then decreased by -19bps to 108.18% in 2026.
  • The last three reported values for Return on Capital Employed were 108.18% (Q1 2026), 90.76% (Q4 2025), and 49.73% (Q3 2025) per Business Quant data.